Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain

Clinical and Experimental Metastasis

Volumn 28, Issue 8, 2011, Pages 899-908

  Qian, Yongzhen ^a   Hua, Emily ^a   Bisht, Kheem ^b   Woditschka, Stephan ^a   Skordos, Konstantine W ^c   Liewehr, David J ^b   Steinberg, Seth M ^b   Brogi, Edi ^d   Akram, Muzaffar M ^d   Killian, J Keith ^b   Edelman, Daniel C ^b   Pineda, Marbin ^b   Scurci, Stephanie ^b   Degenhardt, Yan Y ^c   Laquerre, Sylvie ^c   Lampkin, Thomas A ^c   Meltzer, Paul S ^b   Camphausen, Kevin ^b   Steeg, Patricia S ^a   Palmieri, Diane ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain metastasis; Breast cancer; p53; Plk1; Targeted therapy

Indexed keywords

GSK 461364A; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL DIVISION; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG UPTAKE; ENZYME INHIBITION; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SURVIVAL RATE;

ANIMALS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RADIATION, IONIZING; SURVIVAL RATE; THIOPHENES; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82355181125     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9421-9     Document Type: Article

References (46)

1. RJ Weil D Palmieri JL Bronder, et al. 2005 Breast cancer metastasis to the central nervous system Am J Pathol 167 4 913 920 16192626 10.1016/S0002-9440(10)61180-7 1:CAS:528:DC%2BD2MXhtFKqtLrP (Pubitemid 41416243)
2. PS Steeg KA Camphausen QR Smith 2011 Brain metastases as preventive and therapeutic targets Nat Rev Cancer 11 5 352 363 21472002 10.1038/nrc3053 1:CAS:528:DC%2BC3MXksVCrtro%3D
3. PR Lockman RK Mittapalli KS Taskar, et al. 2010 Heterogeneous blood-tumor barrier permeability determines drug efficacy in mouse brain metastases of breast cancer Clin Cancer Res 16 23 5664 5678 20829328 10.1158/1078-0432.CCR-10- 1564 1:CAS:528:DC%2BC3cXhsFamtL3F
4. DP Fitzgerald D Palmieri E Hua, et al. 2008 Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization Clin Exp Metastasis 25 7 799 810 18649117 10.1007/s10585-008-9193- z
5. M Schmidt H Bastians 2007 Mitotic drug targets and the development of novel anti-mitotic anticancer drugs Drug Resist Updates 10 4-5 162 181 10.1016/j.drup.2007.06.003 1:CAS:528:DC%2BD2sXhtFWhs73N (Pubitemid 47449762)
6. Y Degenhardt T Lampkin 2010 Targeting Polo-like kinase in cancer therapy Clin Cancer Res 16 2 384 389 20068088 10.1158/1078-0432.CCR-09-1380 1:CAS:528:DC%2BC3cXktF2qsbw%3D
7. RJ Freilich AD Seidman LM DeAngelis 1995 Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel Cancer 76 2 232 236 8625097 10.1002/1097-0142(19950715)76:2<232::AID- CNCR2820760212>3.0.CO;2-0 1:STN:280:DyaK283itlShsg%3D%3D
8. D Crivellari O Pagani A Veronesi, et al. 2001 High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel Ann Oncol 12 3 353 356 11332148 10.1023/A:1011132609055 1:STN:280:DC%2BD3MrhsFCjug%3D%3D (Pubitemid 32288692)
9. W Boogerd O Dalesio EM Bais, et al. 1992 Response of brain metastases from breast cancer to systemic chemotherapy Cancer 69 4 972 980 1735089 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P 1:STN:280:DyaK387js1ensA%3D%3D
10. K Strebhardt 2010 Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Nat Rev Drug Discov 9 8 643 660 20671765 10.1038/nrd3184 1:CAS:528:DC%2BC3cXpsVCktrw%3D
11. FA Barr HH Sillje EA Nigg 2004 Polo-like kinases and the orchestration of cell division Nat Rev Mol Cell Biol 5 6 429 440 15173822 10.1038/nrm1401 1:CAS:528:DC%2BD2cXksVarsLk%3D (Pubitemid 38745493)
12. SS Dias C Hogan AM Ochocka, et al. 2009 Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover FEBS Lett 583 22 3543 3548 19833129 10.1016/j.febslet.2009.09.057 1:CAS:528:DC%2BD1MXhsVWls7zO
13. M Lee MJ Daniels AR Venkitaraman 2004 Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression Oncogene 23 4 865 872 14647413 10.1038/sj.onc.1207223 1:CAS:528: DC%2BD2cXntlemuw%3D%3D (Pubitemid 38250931)
14. B Spankuch Y Matthess R Knecht, et al. 2004 Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1 J Natl Cancer Inst 96 11 862 872 15173270 10.1093/jnci/djh146 (Pubitemid 38807607)
15. P Chopra G Sethi SG Dastidar, et al. 2010 Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics Expert Opin Investig Drugs 19 1 27 43 20001553 10.1517/13543780903483191 1:CAS:528:DC%2BD1MXhsFCiu7%2FJ
16. B Spankuch-Schmitt J Bereiter-Hahn M Kaufmann, et al. 2002 Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells J Natl Cancer Inst 94 24 1863 1877 12488480 10.1093/jnci/94.24.1863 1:CAS:528:DC%2BD3sXlsFyisg%3D%3D (Pubitemid 36104631)
17. B Spankuch-Schmitt G Wolf C Solbach, et al. 2002 Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells Oncogene 21 20 3162 3171 12082631 10.1038/sj.onc.1205412 1:CAS:528:DC%2BD38XktFCqu7c%3D (Pubitemid 34548087)
18. JP Cogswell CE Brown JE Bisi, et al. 2000 Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function Cell Growth Differ 11 12 615 623 11149596 1:CAS:528:DC%2BD3MXitVGrtg%3D%3D (Pubitemid 32042984)
19. G Wolf R Hildenbrand C Schwar, et al. 2000 Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer Pathol Res Pract 196 11 753 759 11186170 1:CAS:528: DC%2BD3MXjtFyqtQ%3D%3D
20. W Weichert G Kristiansen KJ Winzer, et al. 2005 Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications Virchows Arch 446 4 442 450 15785925 10.1007/s00428-005-1212-8 1:CAS:528:DC%2BD2MXjslOrtLk%3D (Pubitemid 40674853)
21. A Rizki JD Mott MJ Bissell 2007 Polo-like kinase 1 is involved in invasion through extracellular matrix Cancer Res 67 23 11106 11110 18056432 10.1158/0008-5472.CAN-07-2348 1:CAS:528:DC%2BD2sXhtlyiurvO (Pubitemid 350248532)
22. L Kneisel K Strebhardt A Bernd, et al. 2002 Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease J Cutan Pathol 29 6 354 358 12135466 10.1034/j.1600-0560.2002.290605.x
23. AG Gilmartin MR Bleam MC Richter, et al. 2009 Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis Cancer Res 69 17 6969 6977 19690138 10.1158/0008-5472.CAN-09-0945 1:CAS:528:DC%2BD1MXhtVOmtL3E
24. S Sur R Pagliarini F Bunz, et al. 2009 A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 Proc Natl Acad Sci USA 106 10 3964 3969 19225112 10.1073/pnas.0813333106 1:CAS:528:DC%2BD1MXjt1Gkt74%3D
25. Y Degenhardt J Greshock S Laquerre, et al. 2010 Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability Mol Cancer Ther 9 7 2079 2089 20571075 10.1158/1535-7163.MCT-10-0095 1:CAS:528:DC%2BC3cXhtFertbbF
26. P Bertheau M Espie E Turpin, et al. 2008 TP53 status and response to chemotherapy in breast cancer Pathobiology 75 2 132 139 18544968 10.1159/000123851 1:CAS:528:DC%2BD1cXmvFGksbs%3D (Pubitemid 351820731)
27. M Hampl JA Hampl P Schwarz, et al. 1998 Accumulation of genetic alterations in brain metastases of sporadic breast carcinomas is associated with reduced survival after metastasis Invasion Metastasis 18 2 81 95 10364688 10.1159/000024501 (Pubitemid 29276548)
28. M Hampl JA Hampl G Reiss, et al. 1999 Loss of heterozygosity accumulation in primary breast carcinomas and additionally in corresponding distant metastases is associated with poor outcome Clin Cancer Res 5 6 1417 1425 10389927 1:STN:280:DyaK1Mzhs1Oruw%3D%3D (Pubitemid 29282947)
29. T Yoneda PJ Williams T Hiraga, et al. 2001 A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro J Bone Miner Res 16 8 1486 1495 11499871 10.1359/jbmr.2001.16.8.1486 1:CAS:528:DC%2BD3MXmtVOhur8%3D (Pubitemid 32675200)
30. D Palmieri PR Lockman FC Thomas, et al. 2009 Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks Clin Cancer Res 15 19 6148 6157 19789319 10.1158/1078-0432.CCR-09-1039 1:CAS:528:DC%2BD1MXhtF2lurzF
31. T Sjoblom S Jones LD Wood, et al. 2006 The consensus coding sequences of human breast and colorectal cancers Science 314 5797 268 274 16959974 10.1126/science.1133427 (Pubitemid 44571966)
32. XH Zhang Q Wang W Gerald, et al. 2009 Latent bone metastasis in breast cancer tied to Src-dependent survival signals Cancer Cell 16 1 67 78 19573813 10.1016/j.ccr.2009.05.017 1:CAS:528:DC%2BD1MXhtVWnsL7I
33. RA Irizarry B Hobbs F Collin, et al. 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data Biostatistics 4 2 249 264 12925520 10.1093/biostatistics/4.2.249
34. Olmos D, Allred A, Sharma R, et al (2009) Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. In: ASCO Annual Meeting American Society of Clinical Oncology, Abstract no 3536
35. MA van Vugt AK Gardino R Linding, et al. 2004 A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint PLoS Biol 8 1 e1000287 10.1371/journal.pbio.1000287
36. JF Deeken W Loscher 2007 The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin Cancer Res 13 6 1663 1674 17363519 10.1158/1078-0432.CCR-06-2854 1:CAS:528:DC%2BD2sXivV2gtrg%3D (Pubitemid 46952931)
37. JM Wu MJ Fackler MK Halushka, et al. 2008 Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 7 1938 1946 18381931 10.1158/1078-0432.CCR-07-4082 1:CAS:528:DC%2BD1cXkt1aktbg%3D (Pubitemid 351551102)
38. PS Steeg 2006 Tumor metastasis: mechanistic insights and clinical challenges Nat Med 12 8 895 904 16892035 10.1038/nm1469 1:CAS:528: DC%2BD28Xnsl2iu74%3D (Pubitemid 44175140)
39. X Yang H Li Z Zhou, et al. 2009 Plk1-mediated phosphorylation of Topors regulates p53 stability J Biol Chem 284 28 18588 18592 19473992 10.1074/jbc.C109.001560 1:CAS:528:DC%2BD1MXotVKnsrk%3D
40. S Weger E Hammer R Heilbronn 2005 Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo FEBS Lett 579 22 5007 5012 16122737 10.1016/j.febslet.2005.07.088 1:CAS:528:DC%2BD2MXpvV2ru7o%3D (Pubitemid 41242844)
41. R Rajendra D Malegaonkar P Pungaliya, et al. 2004 Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53 J Biol Chem 279 35 36440 36444 15247280 10.1074/jbc.C400300200 1:CAS:528: DC%2BD2cXmvFCnurc%3D (Pubitemid 39128984)
42. J Momand HH Wu G Dasgupta 2000 MDM2-master regulator of the p53 tumor suppressor protein Gene 242 1-2 15 29 10721693 10.1016/S0378-1119(99)00487-4 1:CAS:528:DC%2BD3cXhsFCjtrs%3D (Pubitemid 30064488)
43. NN Kreis K Sommer M Sanhaji, et al. 2009 Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) Cell Cycle 8 3 460 472 19177004 10.4161/cc.8.3.7651 1:CAS:528:DC%2BD1MXlvFWjtr8%3D
44. N Koida T Ozaki H Yamamoto, et al. 2008 Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation J Biol Chem 283 13 8555 8563 18174154 10.1074/jbc.M710608200 1:CAS:528:DC%2BD1cXjsFCgsbY%3D
45. SM Soond SP Barry G Melino, et al. 2008 p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1 Cell Cycle 7 9 1214 1223 18418051 10.4161/cc.7.9.5777 1:CAS:528:DC%2BD1cXosVKrsLo%3D (Pubitemid 351749275)
46. F Rödel S Keppner G Capalbo, et al. 2010 Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer Am J Pathol 177 2 918 929 20581060 10.2353/ajpath.2010.100040